Results 181 to 190 of about 25,852 (233)

The polypill after acute coronary syndrome: A feasible pill to swallow? [PDF]

Am J Prev Cardiol
Khan SU, Patel KV.
europepmc   +1 more source

Macrophage Iron Metabolism Mediates Immunometabolic Reprogramming and Tissue Homeostasis: From Molecular Mechanisms to Clinical Translation. [PDF]

Cells
Wang M, Wang M, Ying Q, Li Q, Lou X, Dai S, Liu Z.   +6 more
europepmc   +1 more source

Impact of thrombocytopenia on bleeding and cardiovascular outcomes in patients undergoing percutaneous coronary intervention with dual-antiplatelet therapy. [PDF]

Egypt Heart J
Sharma V, Pachori R, Bagrodia V, Agarwal A, Digwal A, Raisinghani Y, Modi N, Gupta V, Vijayvergia T, Jhajharia A, Sharma H, Garg P, Mittal S.   +12 more
europepmc   +1 more source

Hyperglycemia impairs microglia responding to retinal vasculopathy via enhanced norepinephrine-ADRB2 signaling. [PDF]

J Neuroinflammation
Bu S, Mou B, Xiang Z, Zhang L, Hao B, Chen J, Huang L, Ruan X, Liu YU, Zhang Y.   +9 more
europepmc   +1 more source

Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function [PDF]

Thrombosis and Haemostasis, 2010
SummaryThe thienopyridine P2Y12 receptor antagonists clopidogrel and prasugrel prevent arterial thrombosis and are routinely used following percutaneous coronary intervention. However, the optimal level of P2Y12 blockade to effectively inhibit platelet function is unknown.
Robert J Buckland, Atsuhiro Sugidachi, Robert F Storey   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

The Function and Regulation of Platelet P2Y12 Receptor

Cardiovascular Drugs and Therapy, 2021
In addition to the key role in hemostasis and thrombosis, platelets have also been wildly acknowledged as immune regulatory cells and involving in the pathogenesis of inflammation-related diseases. Since purine receptor P2Y12 plays a crucial role in platelet activation, P2Y12 antagonists such as clopidogrel, prasugrel, and ticagrelor have been widely ...
Xiaohua Li, Xia Cao
exaly   +3 more sources

P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor

Heart, 2021
Objective To compare P2Y12 inhibitor monotherapy after 3-month dual antiplatelet therapy (DAPT) with 12-month DAPT according to the type of P2Y12 inhibitor in patients undergoing percutaneous coronary intervention (PCI).
Juwon Kim, Woo Jin Jang, Wang Soo Lee, Ki Hong Choi, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Jin-Ho Choi, Young Bin Song, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Sang Hoon Lee, Ju-Hyeon Oh, Woo Jung Chun, Yong Hwan Park, Eul-Soon Im, Jin-Ok Jeong, Byung Ryul Cho, Seok Kyu Oh, Kyeong Ho Yun, Deok-Kyu Cho, Jong-Young Lee, Young-Youp Koh, Jang-Whan Bae, Jae Woong Choi, Hyuck Jun Yoon, Seung Uk Lee, Jang Hyun Cho, Woong Gil Choi, Seung-Woon Rha, Joo-Yong Hahn   +30 more
openaire   +2 more sources